GlassScriptPhysician profile
Leonard A Bruno
NPI 1538113360
$3,900.57
in general payments reported to CMS, 2019-2025
35 companies · $16.68 in 2025
The $16.68 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,321 · 2020: $227 · 2021: $1,046 · 2022: $924 · 2023: $313 · 2024: $53.40 · 2025: $16.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $641.82 | 2019-2023 | Relistor |
| Nevro Corp. | $447.68 | 2019-2023 | Senza |
| Scilex Pharmaceuticals INC. | $370.03 | 2019-2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $349.47 | 2019-2025 | Xtampza |
| Boston Scientific Corporation | $275.12 | 2021-2024 | Ams 700 |
| Teva Pharmaceuticals USA, INC. | $180.72 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $163.07 | 2019-2022 | |
| Amgen INC. | $157.42 | 2019 | |
| Abbott Laboratories | $155.98 | 2019-2022 | |
| Resmed Corp | $140.16 | 2022 | |
| Daiichi Sankyo INC. | $114.39 | 2019 | |
| Forte Bio-Pharma LLC | $99.79 | 2019-2021 | |
| Almatica Pharma LLC | $92.22 | 2022-2023 | Gralise |
| Arbor Pharmaceuticals, INC. | $82.37 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $78.45 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $59.07 | 2023 | Hymovis |
| Pfizer INC. | $58.43 | 2019-2021 | |
| Grt US Holding, INC. | $47.47 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $36.16 | 2019 | |
| Kaleo, INC. | $35.79 | 2019 | |
| Redhill Biopharma INC. | $32.73 | 2021 | |
| Nalu Medical, INC. | $29.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.47 | 2019 | |
| Biogen, INC. | $25.53 | 2021 | |
| Azurity Pharmaceuticals, INC. | $24.48 | 2023 | Horizant |
| Abbvie INC. | $24.10 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $23.87 | 2023 | Dysport |
| Biohaven Pharmaceutical Holding Company LTD. | $22.38 | 2022 | |
| Lilly USA, LLC | $17.76 | 2019 | |
| Protega Pharmaceutials INC | $17.59 | 2023 | Roxybond |
| Si-Bone, INC. | $17.01 | 2019 | |
| Medtronic USA, INC. | $15.28 | 2019 | |
| Assertio Therapeutics, INC. | $13.69 | 2020 | |
| Horizon Therapeutics Plc | $12.69 | 2022 | |
| Shionogi INC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.